NCT03930004

Brief Summary

Type 1 diabetes mellitus is a chronic autoimmune disease, associated with an increased risk of cardiovascular diseases. The development of cardiomyopathy in type 1 diabetes, independent of hypertension and coronary heart disease, is still controversial. A possible mechanism for diabetic cardiomyopathy is autonomic dysfunction. This study aims to evaluate cardiac function and structure, and to relate them with autonomic dysfunction in type 1 diabetes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 6, 2018

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

February 14, 2019

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 29, 2019

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2019

Completed
Last Updated

October 8, 2019

Status Verified

October 1, 2019

Enrollment Period

1.1 years

First QC Date

February 14, 2019

Last Update Submit

October 6, 2019

Conditions

Outcome Measures

Primary Outcomes (4)

  • Preclinical myocardial dysfunction

    Incidence of patients with alteration in left ventricular myocardial strain (≤ 17% in absolute value).

    At patient inclusion.

  • Left ventricular diastolic dysfunction

    Incidence of patients with signs of diastolic dysfunction: average E/e' ratio (abnormal when \> 14)

    At patient inclusion.

  • Left ventricular hypertrophy

    Incidence of patients with LV mass by linear measurements \> 95 g/m2 if women and \> 115 g/m2 if men.

    At patient inclusion.

  • Left atrial dysfunction

    Incidence of patients with abnormal reservoir strain (normal range: 38%-41%), or abnormal conduit strain (normal range: 21%-25%), or abnormal contractile strain (normal range: 16%-19%).

    At patient inclusion.

Study Arms (2)

Type 1 diabetic patients

Patients diagnosed with type 1 diabetes mellitus with criteria for cardiovascular autonomic neuropathy, asymptomatic, normotensive, with negative medical history of cardiovascular disease. Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function.

Control - Healthy subjects

Fifteen age- and sex-matched healthy control subjects, asymptomatic, normotensive, with negative medical history of cardiovascular disease. Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function.

Eligibility Criteria

Age20 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Selection of patients from a tertiary hospital.

You may qualify if:

  • type 1 diabetes mellitus

You may not qualify if:

  • hypertension
  • coronary artery disease
  • heart valve disease
  • ventricular dysfunction
  • radiotherapy or chemotherapy
  • alcoholism
  • limited acoustic window

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

HU/UFSC

Florianópolis, Santa Catarina, 88036-500, Brazil

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1Diabetic CardiomyopathiesDiabetic Neuropathies

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesCardiomyopathiesHeart DiseasesCardiovascular DiseasesDiabetes ComplicationsPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System Diseases

Study Officials

  • Thais R Weber, MD

    HU/UFSC

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Clinical Director

Study Record Dates

First Submitted

February 14, 2019

First Posted

April 29, 2019

Study Start

July 6, 2018

Primary Completion

August 1, 2019

Study Completion

September 1, 2019

Last Updated

October 8, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share

Locations